Merck KGaA, Pfizer’s immunotherapy fails in lung cancer trial – Reuters
|
Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial
Reuters FRANKFURT (Reuters) – Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said. The results revealed on Thursday mark another setback … |
